Berberine enhances tumor necrosis factor‑related apoptosis‑inducing ligand‑mediated apoptosis in breast cancer

Refaat,Alaa; Abdelhamed,Sherif; Yagita,Hideo; Inoue,Hiroki; Yokoyama,Satoru; Hayakawa,Yoshihiro; Saiki,Ikuo

doi:10.3892/ol.2013.1434

Berberine enhances tumor necrosis factor‑related apoptosis‑inducing ligand‑mediated apoptosis in breast cancer

Authors:
- Alaa Refaat
- Sherif Abdelhamed
- Hideo Yagita
- Hiroki Inoue
- Satoru Yokoyama
- Yoshihiro Hayakawa
- Ikuo Saiki
View Affiliations

Affiliations: Division of Pathogenic Biochemistry, Department of Bioscience, Institute of Natural Medicine, University of Toyama, Toyama 930‑0194, Japan, Department of Immunology, Juntendo University School of Medicine, Tokyo 113‑8421, Japan
Published online on: July 1, 2013 https://doi.org/10.3892/ol.2013.1434
Pages: 840-844

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Berberine (BBR) has been used for the treatment of bacterial and fungal infections and also for cancer‑associated symptoms such as diarrhea. Furthermore, it has been reported that BBR may have direct antitumor effects. Although evidence supports the theory that tumor necrosis factor (TNF)‑related apoptosis‑inducing ligand (TRAIL) is a promising candidate for treating cancer, its usage may be limited due to the resistance to the TRAIL‑induced apoptosis of cancer cells. In the present study, the effect of BBR on TRAIL‑induced antitumor effects was investigated in vitro using recombinant TRAIL and in vivo using a 4T1 murine breast cancer model in combination with anti‑DR5 (death‑inducing TRAIL receptor) monoclonal antibody therapy. BBR sensitized human breast cancer cell lines to TRAIL‑mediated apoptosis in vitro. The combination of BBR and recombinant TRAIL significantly activated caspase‑3 and PARP cleavage in TRAIL‑resistant MDA‑MB‑468 cells. Furthermore, BBR in combination with TRAIL more effectively induced apoptosis compared with coptisine (COP), which is structurally related to BBR. In a murine 4T1 breast cancer model, BBR treatment enhanced the efficacy of anti‑DR5 antibody therapy against primary tumor growth and lung metastasis. Thus, BBR may become a new adjuvant for overcoming the resistance of cancer cells to TRAIL/DR5‑mediated therapy.

View Figures

View References

1	Harris JR, Lippman ME, Veronesi U and Willett W: Breast cancer (1). N Engl J Med. 327:319–328. 1992. View Article : Google Scholar
2	Wald N, Frost C and Cuckle H: Breast cancer screening: the current position. BMJ. 302:845–846. 1991. View Article : Google Scholar : PubMed/NCBI
3	Sotiriou C, Neo SY, McShane LM, Korn EL, Long PM, Jazaeri A, Martiat P, Fox SB, Harris AL and Liu ET: Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci USA. 100:10393–10398. 2003. View Article : Google Scholar : PubMed/NCBI
4	MacFarlane M, Ahmad M, Srinivasula SM, Fernandes-Alnemri T, Cohen GM and Alnemri ES: Identification and molecular cloning of two novel receptors for the cytotoxic ligand TRAIL. J Biol Chem. 272:25417–25420. 1997. View Article : Google Scholar : PubMed/NCBI
5	Pan G, O'Rourke K, Chinnaiyan AM, Gentz R, Ebner R, Ni J and Dixit VM: The receptor for the cytotoxic ligand TRAIL. Science. 276:111–113. 1997. View Article : Google Scholar : PubMed/NCBI
6	Sheridan JP, Marsters SA, Pitti RM, Gurney A, Skubatch M, Baldwin D, Ramakrishnan L, Gray CL, Baker K, Wood WI, Goddard AD, Godowski P and Ashkenazi A: Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science. 277:818–821. 1997. View Article : Google Scholar : PubMed/NCBI
7	Yin S, Xu L, Bandyopadhyay S, Sethi S and Reddy KB: Cisplatin and TRAIL enhance breast cancer stem cell death. Int J Oncol. 39:891–898. 2011.PubMed/NCBI
8	Lin T, Ding Z, Li N, Xu J, Luo G, Liu J and Shen J: Seleno-cyclodextrin sensitises human breast cancer cells to TRAIL-induced apoptosis through DR5 induction and NF-κB suppression. Eur J Cancer. 47:1890–1907. 2011.PubMed/NCBI
9	Lin T, Ding Z, Li N, Xu J, Luo G, Liu J and Shen J: 2-Tellurium-bridged β-cyclodextrin, a thioredoxin reductase inhibitor, sensitizes human breast cancer cells to TRAIL-induced apoptosis through DR5 induction and NF-κB suppression. Carcinogenesis. 32:154–167. 2011.
10	Misaki T, Sagara K, Ojima M, Kakizawa S, Oshima T and Yoshizawa H: Simultaneous determination of berberine, palmatine and coptisine in crude drugs and oriental pharmaceutical preparations by ion-pair high-performance liquid chromatography. Chem Pharm Bull (Tokyo). 30:354–357. 1982. View Article : Google Scholar
11	Kang JX, Liu J, Wang J, He C and Li FP: The extract of huanglian, a medicinal herb, induces cell growth arrest and apoptosis by upregulation of interferon-beta and TNF-alpha in human breast cancer cells. Carcinogenesis. 26:1934–1939. 2005. View Article : Google Scholar : PubMed/NCBI
12	Liu J, He C, Zhou K, Wang J and Kang JX: Coptis extracts enhance the anticancer effect of estrogen receptor antagonists on human breast cancer cells. Biochem Biophys Res Commun. 378:174–178. 2009. View Article : Google Scholar : PubMed/NCBI
13	Kim JB, Yu JH, Ko E, Lee KW, Song AK, Park SY, Shin I, Han W and Noh DY: The alkaloid Berberine inhibits the growth of Anoikis-resistant MCF-7 and MDA-MB-231 breast cancer cell lines by inducing cell cycle arrest. Phytomedicine. 17:436–440. 2010. View Article : Google Scholar : PubMed/NCBI
14	Iizuka N, Miyamoto K, Okita K, Tangoku A, Hayashi H, Yosino S, Abe T, Morioka T, Hazama S and Oka M: Inhibitory effect of Coptidis Rhizoma and berberine on the proliferation of human esophageal cancer cell lines. Cancer Lett. 148:19–25. 2000. View Article : Google Scholar : PubMed/NCBI
15	Tang F, Wang D, Duan C, Huang D, Wu Y, Chen Y, Wang W, Xie C, Meng J, Wang L, Wu B, Liu S, Tian D, Zhu F, He Z, Deng F and Cao Y: Berberine inhibits metastasis of nasopharyngeal carcinoma 5–8F cells by targeting Rho kinase-mediated Ezrin phosphorylation at threonine 567. J Biol Chem. 284:27456–27466. 2009.
16	Jantová S, Cipák L, Cernáková M and Kost'álová D: Effect of berberine on proliferation, cell cycle and apoptosis in HeLa and L1210 cells. J Pharm Pharmacol. 55:1143–1149. 2003.PubMed/NCBI
17	Wang N, Feng Y, Zhu M, Tsang CM, Man K, Tong Y and Tsao SW: Berberine induces autophagic cell death and mitochondrial apoptosis in liver cancer cells: the cellular mechanism. J Cell Biochem. 111:1426–1436. 2010. View Article : Google Scholar : PubMed/NCBI
18	Kim S, Han J, Lee SK, Choi MY, Kim J, Lee J, Jung SP, Kim JS, Kim JH, Choe JH, Lee JE and Nam SJ: Berberine suppresses the TPA-induced MMP-1 and MMP-9 expressions through the inhibition of PKC-α in breast cancer cells. J Surg Res. 176:e21–e29. 2012.PubMed/NCBI
19	Singh T, Vaid M, Katiyar N, Sharma S and Katiyar SK: Berberine, an isoquinoline alkaloid, inhibits melanoma cancer cell migration by reducing the expressions of cyclooxygenase-2, prostaglandin E₂ and prostaglandin E₂ receptors. Carcinogenesis. 32:86–92. 2011. View Article : Google Scholar : PubMed/NCBI
20	Tsang CM, Lau EP, Di K, Cheung PY, Hau PM, Ching YP, Wong YC, Cheung AL, Wan TS, Tong Y, Tsao SW and Feng Y: Berberine inhibits Rho GTPases and cell migration at low doses but induces G2 arrest and apoptosis at high doses in human cancer cells. Int J Mol Med. 24:131–138. 2009.PubMed/NCBI
21	Zhang X, Gu L, Li J, Shah N, He J, Yang L, Hu Q and Zhou M: Degradation of MDM2 by the interaction between berberine and DAXX leads to potent apoptosis in MDM2-overexpressing cancer cells. Cancer Res. 70:9895–9904. 2010. View Article : Google Scholar : PubMed/NCBI
22	Hwang JM, Kuo HC, Tseng TH, Liu JY and Chu CY: Berberine induces apoptosis through a mitochondria/caspases pathway in human hepatoma cells. Arch Toxicol. 80:62–73. 2006. View Article : Google Scholar : PubMed/NCBI
23	Katiyar SK, Meeran SM, Katiyar N and Akhtar S: p53 Cooperates berberine-induced growth inhibition and apoptosis of non-small cell human lung cancer cells in vitro and tumor xenograft growth in vivo. Mol Carcinog. 48:24–37. 2009. View Article : Google Scholar : PubMed/NCBI
24	Kheir MM, Wang Y, Hua L, Hu J, Li L, Lei F and Du L: Acute toxicity of berberine and its correlation with the blood concentration in mice. Food Chem Toxicol. 48:1105–1110. 2010. View Article : Google Scholar : PubMed/NCBI
25	Lee SJ, Noh HJ, Sung EG, Song IH, Kim JY, Kwon TK and Lee TJ: Berberine sensitizes TRAIL-induced apoptosis through proteasome-mediated downregulation of c-FLIP and Mcl-1 proteins. Int J Oncol. 38:485–492. 2011.PubMed/NCBI
26	Takeda K, Yamaguchi N, Akiba H, Kojima Y, Hayakawa Y, Tanner JE, Sayers TJ, Seki N, Okumura K, Yagita H and Smyth MJ: Induction of tumor-specific T cell immunity by anti-DR5 antibody therapy. J Exp Med. 199:437–448. 2004. View Article : Google Scholar : PubMed/NCBI
27	Refaat A, Zhou Y, Suzuki S, Takasaki I, Koizumi K, Yamaoka S, Tabuchi Y, Saiki I and Sakurai H: Distinct roles of transforming growth factor-beta-activated kinase 1 (TAK1)-c-Rel and interferon regulatory factor 4 (IRF4) pathways in human T cell lymphotropic virus 1-transformed T helper 17 cells producing interleukin-9. J Biol Chem. 286:21092–21099. 2011. View Article : Google Scholar
28	Kuo CL, Chi CW and Liu TY: Modulation of apoptosis by berberine through inhibition of cyclooxygenase-2 and Mcl-1 expression in oral cancer cells. In Vivo. 19:247–252. 2005.PubMed/NCBI
29	Hu JP, Nishishita K, Sakai E, Yoshida H, Kato Y, Tsukuba T and Okamoto K: Berberine inhibits RANKL-induced osteoclast formation and survival through suppressing the NF-kappaB and Akt pathways. Eur J Pharmacol. 580:70–79. 2008. View Article : Google Scholar : PubMed/NCBI
30	Bao L, Haque A, Jackson K, Hazari S, Moroz K, Jetly R and Dash S: Increased expression of P-glycoprotein is associated with doxorubicin chemoresistance in the metastatic 4T1 breast cancer model. Am J Pathol. 178:838–852. 2011. View Article : Google Scholar : PubMed/NCBI
31	Kim HS, Kim MJ, Kim EJ, Yang Y, Lee MS and Lim JS: Berberine-induced AMPK activation inhibits the metastatic potential of melanoma cells via reduction of ERK activity and COX-2 protein expression. Biochem Pharmacol. 83:385–394. 2012. View Article : Google Scholar : PubMed/NCBI